Direct-acting antivirals (DAAs) have revolutionized the treatment of chronic hepatitis C virus (HCV) infection, achieving sustained virological response (SVR) in over 95% of patients. This breakthrough has transformed HCV infection from a progressive chronic disease into one that is curable, significantly reducing liver-related complications and mortality. However, viral eradication does not always mean the end of clinical follow-up. Patients with advanced liver disease, comorbidities, or ongoing risk behaviors may remain at risk for disease progression, long-term complications, or reinfection. With the increasing number of individuals achieving SVR, clinicians face the challenge of defining optimal post-cure management strategies, including the frequency and type of monitoring, risk stratification, and preventive measures. This review summarizes current evidence and guideline recommendations for post-SVR care, emphasizing individualized approaches based on baseline liver disease severity, patient comorbidities, and continued exposure to risk factors.